{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:53:08Z","timestamp":1787964788267,"version":"build-2784847793"},"reference-count":151,"publisher":"Open Exploration Publishing","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Explor Target Antitumor Ther"],"accepted":{"date-parts":[[2025,9,18]]},"abstract":"<jats:p xml:lang=\"en\">Gynecological cancer remains one of the leading causes of mortality worldwide. Recent advances in genomic and molecular sequencing have significantly enhanced our understanding of the biological pathways that drive tumor progression and resistance to therapy. Targeted therapies, including monoclonal antibodies (mAbs), have revolutionized cancer treatment by selectively interfering with oncogenic proteins expressed on cancer cells. However, the long-term clinical benefit is often limited due to the emergence of drug resistance, frequently mediated by compensatory signaling pathways or immune escape mechanisms. To overcome these limitations, bispecific antibodies (bsAbs) represent an innovative class of therapeutic agents that have shown promising results across various medical fields. They have been developed to engage two distinct targets simultaneously, such as tumor antigens, immune effectors, or immunomodulatory checkpoints, thereby enhancing anti-tumor activity and reducing the risk of resistance. There are 17 bsAbs approved for clinical use in various countries, with numerous others currently in active development and over 600 bsAbs undergoing clinical trials worldwide. Among these, 11 have received FDA approval for the treatment of hematologic malignancies as well as solid tumors, including uveal melanoma, metastatic non-small cell lung cancer, small cell lung cancer, and biliary tract cancers. Although some studies have explored bsAbs in gynecological cancers, this area remains underdeveloped compared to other oncology fields. Most ongoing studies in this area are still in their early phases (phase I or phase II), and there is a need for optimization in terms of antibody design, efficacy, and safety profiles. Therefore, the purpose of this review is to present a comprehensive summary of the current research on bsAbs in gynecological cancers, with a focus on endometrial, cervical, and ovarian cancers. We will highlight ongoing clinical trials, discuss the mechanisms of action of these agents, and explore their potential benefits in enhancing treatment outcomes.<\/jats:p>","DOI":"10.37349\/etat.2025.1002345","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T05:28:21Z","timestamp":1762406901000},"update-policy":"https:\/\/doi.org\/10.37349\/open_exploration_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities"],"prefix":"10.37349","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-0688","authenticated-orcid":false,"given":"Sara","family":"Parola","sequence":"first","affiliation":[{"name":"Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0602-8667","authenticated-orcid":false,"given":"Ilaria","family":"Colombo","sequence":"additional","affiliation":[{"name":"Medical Oncology, Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21850","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040770","article-title":"Recent Therapeutic Advances in Gynecologic Oncology: A Review","volume":"16","author":"Wilson","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"6443","DOI":"10.21873\/anticanres.13858","article-title":"Establishment of Drug-resistant Cell Lines as a Model in Experimental Oncology: A Review","volume":"39","author":"Amaral","year":"2019","journal-title":"Anticancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122104","article-title":"Drug resistance and immunotherapy in gynecologic cancers","volume":"332","author":"Vemula","year":"2023","journal-title":"Life Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231173183","article-title":"The role of PARP inhibitor combination therapy in ovarian cancer","volume":"15","author":"Hockings","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1\/GOG 3004 Trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","article-title":"Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial","volume":"32","author":"Wu","year":"2021","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23136911","article-title":"The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects","volume":"23","author":"Mao","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123220","article-title":"Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery","volume":"15","author":"Colombo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142545","article-title":"Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer","volume":"16","author":"Sato","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ygyno.2024.04.008","article-title":"Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging","volume":"186","author":"Espinosa","year":"2024","journal-title":"Gynecol Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000152","article-title":"Endometrial cancer: molecular classification and future treatments","volume":"1","author":"Corr","year":"2022","journal-title":"BMJ Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab Plus Carboplatin\/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132478","article-title":"Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells","volume":"16","author":"Garg","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"304","DOI":"10.20517\/cdr.2021.147","article-title":"Mechanisms of chemotherapy resistance in ovarian cancer","volume":"5","author":"Ortiz","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Arain A, Muhsen IN, Abudayyeh A, Abdelrahim M. Chapter 11 - Chemoresistance in uterine cancer: Mechanisms of resistance and current therapies. Academic Press; 2021. pp. 267\u201381.","DOI":"10.1016\/B978-0-12-824299-5.00013-7"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02169-z","article-title":"Immune microenvironment and molecular mechanisms in endometrial cancer: implications for resistance and innovative treatments","volume":"16","author":"Chen","year":"2025","journal-title":"Discov Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.adcanc.2022.100074","article-title":"Insights into therapy resistance in cervical cancer","volume":"6","author":"George","year":"2022","journal-title":"Adv Cancer Biol Metastasis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/biom15050639","article-title":"Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy","volume":"15","author":"Lizama-Mu\u00f1oz","year":"2025","journal-title":"Biomolecules"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The Therapeutic Potential of Nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"C29","DOI":"10.1152\/ajpcell.00280.2019","article-title":"Extracellular vesicles as biomarkers and therapeutic targets for cancer","volume":"318","author":"Urabe","year":"2020","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2024.1352014","article-title":"Design and engineering of bispecific antibodies: insights and practical considerations","volume":"12","author":"Madsen","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02270-4","article-title":"Nanobodies and their derivatives: pioneering the future of cancer immunotherapy","volume":"23","author":"Li","year":"2025","journal-title":"Cell Commun Signal"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/biom13030465","article-title":"CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy","volume":"13","author":"Zhang","year":"2023","journal-title":"Biomolecules"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1016\/j.ymthe.2024.05.039","article-title":"Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies","volume":"32","author":"Al","year":"2024","journal-title":"Mol Ther"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00250-1","article-title":"Recent advances and challenges of bispecific antibodies in solid tumors","volume":"10","author":"Wu","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus Chemotherapy in NSCLC with","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2113697","article-title":"A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer","volume":"11","author":"Avanzino","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663379","article-title":"Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition","volume":"12","author":"Yeku","year":"2021","journal-title":"Front Immunol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101772","article-title":"Exploring T-cell bispecific antibodies in gynecologic malignancy","volume":"59","author":"O\u2019Brien","year":"2025","journal-title":"Gynecol Oncol Rep"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1486799","article-title":"The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade","volume":"16","author":"Bielski","year":"2025","journal-title":"Front Immunol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ygyno.2023.12.028","article-title":"A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)","volume":"182","author":"Lumish","year":"2024","journal-title":"Gynecol Oncol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1001\/jamaoncol.2024.2145","article-title":"Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial","volume":"10","author":"Birrer","year":"2024","journal-title":"JAMA Oncol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-017-0072-7","article-title":"The development of bispecific antibodies and their applications in tumor immune escape","volume":"6","author":"Zhang","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3390\/ph14090884","article-title":"Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies","volume":"14","author":"Antonarelli","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ymeth.2013.06.036","article-title":"Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions","volume":"65","author":"Kellner","year":"2014","journal-title":"Methods"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168947","article-title":"The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies","volume":"22","author":"Gogesch","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190379","article-title":"Cytokine release syndrome and cancer immunotherapies \u2013 historical challenges and promising futures","volume":"14","author":"Shah","year":"2023","journal-title":"Front Immunol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41423-020-0417-8","article-title":"Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics","volume":"17","author":"Li","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.abg1209","article-title":"Bispecific antibodies","volume":"372","author":"Brinkmann","year":"2021","journal-title":"Science"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-35678-4","article-title":"Structural insights into the bi-specific cross-over dual variable antibody architecture by cryo-EM","volume":"13","author":"Fernandez-Martinez","year":"2023","journal-title":"Sci Rep"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888838","article-title":"A Generic Strategy to Generate Bifunctional Two-in-One Antibodies by Chicken Immunization","volume":"13","author":"Harwardt","year":"2022","journal-title":"Front Immunol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3390\/antib8030043","article-title":"Design and Production of Bispecific Antibodies","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1186\/s40643-022-00562-y","article-title":"Excellent removal of knob-into-hole bispecific antibody byproducts and impurities in a single-capture chromatography","volume":"9","author":"Chen","year":"2022","journal-title":"Bioresour Bioprocess"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ymeth.2018.11.008","article-title":"Engineering therapeutic bispecific antibodies using CrossMab technology","volume":"154","author":"Klein","year":"2019","journal-title":"Methods"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2019.11.014","article-title":"Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours","volume":"317","author":"Debie","year":"2020","journal-title":"J Control Release"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.omto.2019.02.004","article-title":"Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow","volume":"14","author":"Ahamadi-Fesharaki","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ymeth.2018.09.005","article-title":"Structural diversity and flexibility of diabodies","volume":"154","author":"Kwon","year":"2019","journal-title":"Methods"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.3390\/life11060465","article-title":"BiTEs, DARTS, BiKEs and TriKEs\u2014Are Antibody Based Therapies Changing the Future Treatment of AML?","volume":"11","author":"Allen","year":"2021","journal-title":"Life (Basel)"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark Res"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ymeth.2018.07.014","article-title":"Generation of Fabs-in-tandem immunoglobulin molecules for dual-specific targeting","volume":"154","author":"Gong","year":"2019","journal-title":"Methods"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11523-015-0391-8","article-title":"Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells","volume":"11","author":"Schmohl","year":"2016","journal-title":"Target Oncol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.20892\/j.issn.2095-3941.2020.0399","article-title":"Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers","volume":"17","author":"Cheng","year":"2020","journal-title":"Cancer Biol Med"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cpt.1961","article-title":"Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology","volume":"108","author":"Betts","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1007\/s00432-020-03404-6","article-title":"Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy","volume":"146","author":"Huang","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/cpt.651","article-title":"Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment","volume":"101","author":"Yuraszeck","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102106","article-title":"AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial","volume":"62","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-022-02810-z","article-title":"High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer","volume":"20","author":"Mollavelioglu","year":"2022","journal-title":"World J Surg Oncol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1158\/2159-8290.CD-21-0257","article-title":"Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity","volume":"11","author":"Burton","year":"2021","journal-title":"Cancer Discov"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.apsb.2020.04.012","article-title":"Recent advances of antibody drug conjugates for clinical applications","volume":"10","author":"Zhao","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100821","article-title":"41P Phase I analysis of ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer","volume":"8","author":"Moore","year":"2023","journal-title":"ESMO Open"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"S516","DOI":"10.1016\/j.annonc.2023.09.1933","article-title":"754P Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study","volume":"34","author":"O\u2019Cearbhaill","year":"2023","journal-title":"Ann Oncol"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100599","article-title":"127P REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study","volume":"20","author":"Winer","year":"2023","journal-title":"Immuno-Oncol Technol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1097\/IGC.0000000000000286","article-title":"Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study","volume":"24","author":"Berek","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002015","article-title":"Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors","volume":"9","author":"Luke","year":"2021","journal-title":"J Immunother Cancer"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03790-7","article-title":"Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors","volume":"73","author":"Geva","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"S569","DOI":"10.1016\/j.annonc.2024.08.811","article-title":"750P Phase I safety and efficacy of brenetafusp, a PRAME \u00d7 CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)","volume":"35","author":"Friedman","year":"2024","journal-title":"Ann Oncol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.523","article-title":"523\u2005Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors","volume":"9","author":"Shum","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.821","article-title":"760P Cadonilimab with neoadjuvant chemotherapy in advanced ovarian cancer patients (AK104-IIT-003): An open, prospective, single arm, phase II trial","volume":"35","author":"Tang","year":"2024","journal-title":"Ann Oncol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat Med"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008037","article-title":"Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors","volume":"12","author":"Frentzas","year":"2024","journal-title":"J Immunother Cancer"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13461-0","article-title":"The role of MUC16 in tumor biology and tumor immunology in ovarian cancer","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Cancer"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5632","article-title":"A phase 1\/2 study of ubamatamab (REGN4018), a MUC16\u00d7CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti\u2013PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer","volume":"42","author":"Van","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36922\/td.4926","article-title":"EpCAM-targeting cancer immunotherapies: Evidence from clinical studies and the way forward","volume":"4","author":"Makafui","year":"2025","journal-title":"Tumor Discovery"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int J Cancer"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","article-title":"Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM \u00d7 anti-CD3 antibody: a phase I\/II study","volume":"13","author":"Burges","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.5528","article-title":"Phase II trial of intraperitoneal (IP) administration of catumaxomab (C) as consolidation therapy for patients (pts) with relapsed epithelial ovarian cancer (OC) in second or third complete remission: GEICO 1001 study","volume":"32","author":"Romero","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref102","unstructured":"Lindis Biotech and Pharmanovia announce European marketing authorisation approval for a first-in-class treatment [Internet]. Basildon: Pharmanovia; c2025. Available from: https:\/\/pharmanovia.com\/news\/lindis-biotech-and-pharmanovia-announce-european-marketing-authorisation-approval-for-catumaxomab-a-first-in-class-treatment-for-malignant-ascites\/"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40265-025-02187-9","article-title":"Catumaxomab: First Approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092283","article-title":"The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets","volume":"14","author":"Giordano","year":"2022","journal-title":"Cancers (Basel)"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1007\/s10528-024-10945-9","article-title":"The CD40\/CD40L Pathway Regulates the Aggressiveness of Ovarian Cancer Cells via the Activation of Regulatory B Cells","volume":"[Epub ahead of print]","author":"Ma","year":"2024","journal-title":"Biochem Genet"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.12316","article-title":"Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation (Review)","volume":"24","author":"Du","year":"2021","journal-title":"Mol Med Rep"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030679","article-title":"Claudin 18.2 as a New Biomarker in Gastric Cancer\u2014What Should We Know?","volume":"16","author":"Mathias-Machado","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"782","DOI":"10.2119\/molmed.2015.00083","article-title":"Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy","volume":"21","author":"Lin","year":"2015","journal-title":"Mol Med"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.430","article-title":"430\u2005A phase 1b\/II clinical study of AK112, a PD-1\/VEGF bispecific antibody, in combination with olaparib in BRCA germline wild-type platinum sensitive recurrent ovarian cancer","volume":"9","author":"Wu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9019","article-title":"A phase II study of AK112 (PD-1\/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer","volume":"40","author":"Zhao","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5509","article-title":"Cadonilimab plus platinum-based chemotherapy \u00b1 bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses of COMPASSION-16","volume":"43","author":"Sun","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol Oncol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"S1044","DOI":"10.1016\/j.annonc.2021.08.1489","article-title":"1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)","volume":"32","author":"Ku","year":"2021","journal-title":"Ann Oncol"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.2217\/fon-2022-0595","article-title":"HERIZON-GEA-01: Zanidatamab + chemo \u00b1 tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma","volume":"18","author":"Tabernero","year":"2022","journal-title":"Future Oncol"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"367","DOI":"10.21873\/invivo.13837","article-title":"Clinicopathological Significance of Claudin-6 Immunoreactivity in Low-grade, Early-stage Endometrioid Endometrial Carcinoma","volume":"39","author":"Lee","year":"2025","journal-title":"In Vivo"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.2147\/OTT.S174618","article-title":"Knockdown of CLDN6 inhibits cell proliferation and migration via PI3K\/AKT\/mTOR signaling pathway in endometrial carcinoma cell line HEC-1-B","volume":"11","author":"Cao","year":"2018","journal-title":"Onco Targets Ther"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.celrep.2014.09.053","article-title":"Structure and cancer immunotherapy of the B7 family member B7x","volume":"9","author":"Jeon","year":"2014","journal-title":"Cell Rep"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142519","article-title":"B7H4 Role in Solid Cancers: A Review of the Literature","volume":"16","author":"Dawidowicz","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.5858\/arpa.2022-0182-OA","article-title":"B7-H4 Further Stratifies Patients With Endometrial Cancer Exhibiting a Nonspecific Molecular Profile","volume":"147","author":"Zong","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.humpath.2021.04.003","article-title":"Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas","volume":"113","author":"Niu","year":"2021","journal-title":"Hum Pathol"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"252","DOI":"10.5603\/gpl.96605","article-title":"Expression of B7-H4 in endometrial cancer and its impact on patients\u2019 prognosis","volume":"95","author":"Gorzelnik","year":"2024","journal-title":"Ginekol Pol"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115355","article-title":"Manipulating TGF-\u03b2 signaling to optimize immunotherapy for cervical cancer","volume":"166","author":"Yin","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1158\/1078-0432.CCR-22-1779","article-title":"Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer","volume":"28","author":"Miller","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1488730","article-title":"The potential role of HPV oncoproteins in the PD-L1\/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy","volume":"14","author":"Li","year":"2024","journal-title":"Front Oncol"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01045-x","article-title":"The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1","volume":"14","author":"Yi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1097\/JS9.0000000000001226","article-title":"Single dual-specific anti-PD-L1\/TGF-\u03b2 antibody synergizes with chemotherapy as neoadjuvant treatment for pancreatic ductal adenocarcinoma: a preclinical experimental study","volume":"110","author":"Zhang","year":"2024","journal-title":"Int J Surg"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179736","article-title":"Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data","volume":"25","author":"Bayly-McCredie","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"ref130","unstructured":"Chennapragada SS, Ramadas P. Bispecific Antibody Toxicity"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-22-3667","article-title":"Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies","volume":"29","author":"Leclercq-Cohen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125838","article-title":"Bispecific Antibodies in Solid Tumors: Advances and Challenges","volume":"26","author":"Shan","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, A TCR\/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/bjh.19455","article-title":"Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high","volume":"205","author":"Grigg","year":"2024","journal-title":"Br J Haematol"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111430","article-title":"The target antigen determines the mechanism of acquired resistance to T cell-based therapies","volume":"41","author":"Mart\u00ednez-Sabadell","year":"2022","journal-title":"Cell Rep"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21445-4","article-title":"Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation","volume":"12","author":"Arenas","year":"2021","journal-title":"Nat Commun"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.68","article-title":"T-cell ligands modulate the cytolytic activity of the CD33\/CD3 BiTE antibody construct, AMG 330","volume":"5","author":"Laszlo","year":"2015","journal-title":"Blood Cancer J"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to Biotherapeutics \u2013 The Role of Anti-drug Immune Complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front Immunol"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153849","article-title":"Tumor Immune Microenvironment in Gynecologic Cancers","volume":"15","author":"Margul","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coi.2016.02.006","article-title":"Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection","volume":"40","author":"Zhukovsky","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-648","article-title":"Abstract 648: Activity of BNT327\/PM8002 (PD-L1 x VEGF-A bispecific antibody) in combination with BNT325\/DB-1305 (TROP2 ADC) in solid tumors: Early preclinical and clinical evidence to support BNT327 + ADC combinations","volume":"85","author":"Hamilton","year":"2025","journal-title":"Cancer Res"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16838-w","article-title":"Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody","volume":"11","author":"Geiger","year":"2020","journal-title":"Nat Commun"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202205532","article-title":"Lipid Nanoparticle Delivery System for mRNA Encoding B7H3-redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors","volume":"10","author":"Huang","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41587-022-01456-2","article-title":"Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins","volume":"41","author":"Pance","year":"2023","journal-title":"Nat Biotechnol"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","article-title":"Antibody targeting of E3 ubiquitin ligases for receptor degradation","volume":"610","author":"Marei","year":"2022","journal-title":"Nature"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90096-8","article-title":"A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells","volume":"11","author":"Harris","year":"2021","journal-title":"Sci Rep"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2024.104265","article-title":"Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: Where do we stand today?","volume":"54","author":"Zhou","year":"2025","journal-title":"Presse Med"}],"container-title":["Exploration of Targeted Anti-tumor Therapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T05:28:22Z","timestamp":1762406902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.explorationpub.com\/Journals\/etat\/Article\/1002345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":151,"URL":"https:\/\/doi.org\/10.37349\/etat.2025.1002345","archive":["Portico","Portico"],"relation":{},"ISSN":["2692-3114"],"issn-type":[{"value":"2692-3114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"2025-04-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-06","order":2,"name":"published","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1002345"}}